ArticleBMC public health2022
Cannabidiol use and perceptions in France: a national survey.
Article in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- The effects of oral cannabidiol supplementation on blood pressure in adults: a systematic review of randomised controlled trials.Journal of cannabis research · 2026Pooled it
- Influence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial.Translational vision science & technology · 2025Trial
- Regulation and Use of Cannabidiol in Croatia Compared with Selected European and International Models: From Consumer Products to Clinical Practice.Journal of clinical medicine · 2026Review
- Healthcare Providers' Acceptability of Cannabis And Cannabidiol to Manage Parkinson's Disease in France.Current therapeutic research, clinical and experimental · 2026Article
- Insights into public use and attitudes of cannabidiol (CBD) in England, Wales and Northern Ireland: secondary analysis of an official statistic consumer survey, Food and You 2.BMJ public health · 2026Article
- Differences in Cannabis and Cannabidiol Attitudes, Perceptions, and Behaviors Between US Adolescents Receiving Mood Disorder Treatment and Their Parents Across Legal Contexts.International journal of environmental research and public health · 2025Article
- Relationships Between Motives for Cannabis and Cannabidiol Use in People Who Co-Use: Results From the European Web Survey on Drugs.Drug and alcohol review · 2025Article
- Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey.Parkinson's disease · 2025Article
- A multi-market comparison of composition, formulation, and label content of CBD e-liquids.iScience · 2024Article
- Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.Pain and therapy · 2024Review
- Acceptability of and attitudes to the therapeutic use of cannabis and cannabidiol in people with Parkinson's disease: A French survey.Clinical parkinsonism & related disorders · 2024Article
- Knowledge and Attitudes of Cannabidiol in Croatia among Students, Physicians, and Pharmacists.Pharmacy (Basel, Switzerland) · 2023Article
- Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.BMC public health · 2023Article
- Cannabis as a Source of Approved Drugs: A New Look at an Old Problem.Molecules (Basel, Switzerland) · 2023Review
- Cannabidiol and brain function: current knowledge and future perspectives.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabidiol (CBD), a safe, non-intoxicating cannabis component, is growing in popularity in Europe and worldwide. However, CBD EU regulation is blurry, and consequent labelling and product quality issues may have implications for public health. There is therefore a need to assess the prevalence and perceived harmfulness of CBD use in EU countries, as well as to characterise CBD users. We aimed to do so in the French population.
methodsIn December 2021, an online survey was conducted in a sample respecting the French adult population structure for key demographic variables. Sociodemographic, behavioural and CBD perception data were collected. Three separate regressions were performed to identify correlates of i) having heard of CBD, ii) using CBD, iii) perceived harmfulness of CBD. A hierarchical classification was also performed to identify profiles of CBD users.
resultsThe study sample comprised 1969 adults, of whom 69.2% had heard of CBD and 10.1% used it. Less than half (46.8%) of the former considered it harmful. Having heard of CBD was associated with younger age, being born in France, tobacco use, and cannabis use. CBD use was associated with younger age, tobacco use, cannabis use, poor self-reported general health status, and positive perception of alternative medicines. Cluster analysis revealed four different CBD user profiles based on socio-demographics and behavioural characteristics.
conclusionTen percent of the adults in this French study used CBD, and several user profiles emerged. Our results indirectly advocate clearer European CBD regulations to ensure safe and high-quality products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.